PharmaLogic, a contract development and manufacturing organization (CDMO) and radiopharmacy solutions provider, opened its radiopharmaceutical production and research facility in the Bronx, New York. Acquired in 2022, the facility has undergone renovations and boasts state-of-the-art equipment.
The Bronx facility further strengthens PharmaLogic's position as a major player in the radiopharmaceutical market. The investment underscores the company's dedication to improving patient access to clinically relevant radiopharmaceuticals while simultaneously pioneering the next generation of novel compounds. This state-of-the-art production and laboratory space will empower PharmaLogic to not only scale up current production, but also channel significant resources towards the research and development of groundbreaking new radiopharmaceuticals.
"This strategic investment in our production and research capabilities reinforces our unwavering commitment to propelling the field of molecular imaging and theranostics forward, ultimately leading to significant advancements in patient care," remarked D. Scott Holbrook, Chief Strategy Officer and General Manager of PharmaLogic. "By developing and delivering innovative radiopharmaceuticals, we strive to equip the medical community with cutting-edge diagnostic and therapeutic tools."
